- Home
- ZEPP vs SLS Comparison
ZEPP vs SLS Comparison
Compare ZEPP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- SLS
- Stock Information
- Founded
- ZEPP 2013
- SLS 2012
- Country
- ZEPP Netherlands
- SLS United States
- Employees
- ZEPP N/A
- SLS N/A
- Industry
- ZEPP Computer Manufacturing
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- SLS Health Care
- Exchange
- ZEPP Nasdaq
- SLS Nasdaq
- Market Cap
- ZEPP 148.3M
- SLS 165.6M
- IPO Year
- ZEPP N/A
- SLS N/A
- Fundamental
- Price
- ZEPP $33.76
- SLS $1.60
- Analyst Decision
- ZEPP
- SLS Strong Buy
- Analyst Count
- ZEPP 0
- SLS 1
- Target Price
- ZEPP N/A
- SLS $7.00
- AVG Volume (30 Days)
- ZEPP 540.1K
- SLS 1.8M
- Earning Date
- ZEPP 08-03-2025
- SLS 08-12-2025
- Dividend Yield
- ZEPP N/A
- SLS N/A
- EPS Growth
- ZEPP N/A
- SLS N/A
- EPS
- ZEPP N/A
- SLS N/A
- Revenue
- ZEPP $199,947,000.00
- SLS N/A
- Revenue This Year
- ZEPP $758.69
- SLS N/A
- Revenue Next Year
- ZEPP N/A
- SLS N/A
- P/E Ratio
- ZEPP N/A
- SLS N/A
- Revenue Growth
- ZEPP N/A
- SLS N/A
- 52 Week Low
- ZEPP $2.13
- SLS $0.77
- 52 Week High
- ZEPP $38.59
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- ZEPP 84.42
- SLS 39.29
- Support Level
- ZEPP $23.10
- SLS $1.50
- Resistance Level
- ZEPP $38.59
- SLS $1.66
- Average True Range (ATR)
- ZEPP 3.30
- SLS 0.10
- MACD
- ZEPP 1.52
- SLS -0.01
- Stochastic Oscillator
- ZEPP 84.23
- SLS 18.33
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.